MEI Pharma Inc. (NASDAQ:MEIP) went down by -7.54% from its latest closing price compared to the recent 1-year high of $2.20. The company’s stock price has collected -4.29% of loss in the last five trading sessions.
Is It Worth Investing in MEI Pharma Inc. (NASDAQ :MEIP) Right Now?
Plus, the 36-month beta value for MEIP is at 0.98. Opinions of the stock are interesting as 4 analysts out of 6 who provided ratings for MEI Pharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases “World’s Most Powerful Data Center CPU”. It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We’ve put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
The average price from analysts is $2.52, which is $3.25 above the current price. MEIP currently public float of 132.62M and currently shorts hold a 3.44% ratio of that float. Today, the average trading volume of MEIP was 1.27M shares.
MEIP’s Market Performance
MEIP stocks went down by -4.29% for the week, with a monthly jump of 6.62% and a quarterly performance of 4.93%, while its annual performance rate touched -83.39%. The volatility ratio for the week stands at 7.58% while the volatility levels for the past 30 days are set at 6.50% for MEI Pharma Inc. The simple moving average for the period of the last 20 days is -1.55% for MEIP stocks with a simple moving average of -26.54% for the last 200 days.
Analysts’ Opinion of MEIP
Many brokerage firms have already submitted their reports for MEIP stocks, with Wells Fargo repeating the rating for MEIP by listing it as a “Equal Weight.” The predicted price for MEIP in the upcoming period, according to Wells Fargo is $2 based on the research report published on March 25th of the previous year 2022.
Stifel, on the other hand, stated in their research note that they expect to see MEIP reach a price target of $2, previously predicting the price at $6. The rating they have provided for MEIP stocks is “Hold” according to the report published on March 25th, 2022.
Jefferies gave a rating of “Hold” to MEIP, setting the target price at $1 in the report published on March 25th of the previous year.
MEIP Trading at 7.83% from the 50-Day Moving Average
After a stumble in the market that brought MEIP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.53% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 7.58%, as shares surge +4.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.65% lower at present.
During the last 5 trading sessions, MEIP fell by -4.29%, which changed the moving average for the period of 200-days by -43.57% in comparison to the 20-day moving average, which settled at $0.3247. In addition, MEI Pharma Inc. saw 30.95% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MEIP
Current profitability levels for the company are sitting at:
- -185.48 for the present operating margin
- +96.97 for the gross margin
The net margin for MEI Pharma Inc. stands at -133.80. Equity return is now at value -92.80, with -28.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.84.